about
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb bindingRegulatable systemic production of monoclonal antibodies by in vivo muscle electroporationElicitation of structure-specific antibodies by epitope scaffoldsPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesAntibodies on demand: a fast method for the production of human scFvs with minimal amounts of antigenMonoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cellsSelection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.n-CoDeR concept: unique types of antibodies for diagnostic use and therapy.Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A.Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeastDesign, synthesis, and biological evaluation of a biyouyanagin compound libraryDifferences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.New approaches in the treatment of asthma.Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in miceEffect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.Papillomavirus-like particle based vaccines: cervical cancer and beyond.Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.Chemokines: agents for the immunotherapy of cancer?Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.Vectored antibody gene delivery for the prevention or treatment of HIV infection.Medical applications of leukocyte surface molecules--the CD moleculesAnalytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody.Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.Single-domain antibody fragments with high conformational stability.Hazard identification and risk assessment for biologics targeting the immune system.An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.Electrochemiluminescence in bioanalysis.Novel methods of targeted drug delivery: the potential of multifunctional nanoparticles.Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.Tumor-targeted immune complex formation: effects on myeloid cell activation and tumor-directed immune cell migration.Recovering antibody secretion using a hapten ligand as a chemical chaperone.AbDesign: An algorithm for combinatorial backbone design guided by natural conformations and sequences.Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment
P2860
Q24291716-DE20752A-7D27-47B1-88F5-A4895E2C64ABQ24806498-EF3A6AE0-2AB8-4CF0-BFB4-B102A48FD715Q27664711-D2E87A02-4345-49EB-BC54-ABE59F765CC6Q27690917-8EB57444-AA56-4214-BFFF-3CE2BDB25394Q28743142-3BA51438-9732-43E3-A7B3-848003A60323Q30489241-A66CFE50-E994-4FE9-9391-9D65EA691C06Q30790872-6A7C7EA2-871E-4E4B-95EE-87F18A594159Q30835165-D8B3637F-9311-4AAF-B1A1-F24A27E6044AQ31016741-D30A50D8-58A8-476F-8485-885610A8BCEDQ31043274-CB2E424E-6861-45DF-89A0-B4337E2ED321Q31067966-A0021C51-792F-457A-82C2-4E5FC953A101Q33662280-9D9C627D-1723-40D7-8FD7-C7AF3F073C7BQ33796299-88881A92-C51F-4C00-87C2-58CE55C8F3C2Q34102657-FEAE02CC-5A4D-4445-B304-3F8D0FEBA140Q34192933-52A5B5CA-8D1F-44B5-B4AC-AF94C906A7B9Q34276582-CF7E511D-1AB9-4B45-92F6-A595C393501CQ34431577-16FFB9AD-B801-441E-AFAB-00036B2B9518Q34451862-8D010CFA-7E36-4F2C-B37C-C32CA45AF985Q34526792-5C4F30A2-848F-4CF4-BF92-237F190DB967Q34576416-229808D8-10F3-40B8-AA31-A255DD5B5520Q35581131-F6756DEC-1831-46B7-AE21-5137116F4643Q35664155-6F66F0BE-A438-47C1-A789-E389AFEB6F7AQ35690889-1069D529-5331-4FEE-BBBE-D1AABD362C2DQ35918866-1ADD47D2-70DD-4649-A11C-CD11C3B18838Q36066311-4027E884-18D7-4410-87B4-620DA5E2DC8BQ36536313-2067E8CF-A945-4B40-965F-0BA92F417FB2Q36639059-E970204D-EDD7-48BB-81D3-7812FD10B02CQ37126041-62DE16A9-104A-47E1-90EF-78715948FF18Q37370515-D32B74CC-1F27-4B36-B5D9-FEB66A1D6C48Q37810142-ED3EA80B-C234-431C-A12B-DD3290A27388Q38177370-4F165C16-4138-43B5-9845-AD8439DBAD1CQ40146896-CEACFEAB-C0CA-43EF-9880-8DAD2336D41FQ40287051-84A44B79-847B-43AE-8C69-FD61593FFC9EQ40448458-A5E6A9A9-6C1B-4F7A-A4CD-3FBD0AE81591Q40694495-A62FFC80-6B72-4F3B-8C59-D484F67DC3BDQ40738763-B6E00990-5D8F-4F82-B248-88C94A358FB4Q40782700-CEE09B67-6259-4E42-8523-1EEB12D595F5Q41451876-2E9EACB3-53A8-49CE-961C-B67DCCC0282AQ42165272-BA392275-3868-43C8-8EEB-AE3465653487Q42732125-B43435DA-A319-4C88-AF95-231A62A24393
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical trials of antibody therapy.
@ast
Clinical trials of antibody therapy.
@en
type
label
Clinical trials of antibody therapy.
@ast
Clinical trials of antibody therapy.
@en
prefLabel
Clinical trials of antibody therapy.
@ast
Clinical trials of antibody therapy.
@en
P1433
P1476
Clinical trials of antibody therapy.
@en
P2093
Glennie MJ
Johnson PW
P304
P356
10.1016/S0167-5699(00)01669-8
P577
2000-08-01T00:00:00Z